Pharmacokinetics, Bioequivalence, and Safety Evaluation of Two Voriconazole Tablets in Healthy Chinese Volunteers
Clinical Pharmacology in Drug Development · 2026-04 · 15 (4)
DOI: 10.1002/cpdd.70058 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 10.04.2026. Verfasst von Pan Luo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Antifungal Agents, Drugs, Generic, Voriconazole. Die Arbeit nennt 16 Literaturangaben. Gefördert von: Wuhan Qirui Pharmaceutical Co., Ltd.
Abstract (Originalsprache)
Voriconazole is a broad‐spectrum antifungal agent belonging to the triazole class, exhibiting significant efficacy against a diverse array of pathogenic organisms. This study aimed to assess the pharmacokinetic properties, bioequivalence, and safety profiles of two oral formulations of voriconazole tablets. An open‐label, randomized, two‐period, two‐sequence crossover, Phase I bioequivalence trial was conducted involving healthy Chinese volunteers under fasting conditions. During each study period, participants were administered a single 200 mg dose of either the generic (test) or branded (reference) voriconazole tablet, with treatment sequences assigned randomly. Blood samples were collected at various time points before and after administration to determine plasma voriconazole concentrations. The study assessed bioequivalence by calculating the maximum concentration (C max ) and the area under the concentration–time curve (AUC). Adverse events (AEs) were systematically documented. A total of seventy healthy volunteers were recruited, with 68 participants who received voriconazole included in the final analysis. The geometric mean ratios (GMR) of the test tablet to the reference for C max , the area under the concentration curve from time 0 to the last measurable time point (AUC 0–t ), and the area under the concentration curve from time 0 extrapolated to infinity (AUC 0–inf ) were determined to be 1.03, 0.98, and 0.97, respectively, under fasting conditions. These values met the established criteria for bioequivalence acceptance. Furthermore, both the test and reference formulations of voriconazole were well tolerated. The findings indicate that the test and reference voriconazole tablets are bioequivalent and possess similar safety profiles in healthy Chinese volunteers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Clinical Pharmacology, Wuhan Createrna Science and Technology Co., Ltd., Wuhan, China.
Förderung
- Wuhan Qirui Pharmaceutical Co., Ltd
Zitieren
APA
Luo, P., Lei, Y., Liu, C., Du, J., Deng, X., Yu, H., Qi, X., He, Z., Zhang, D., Zuo, Q., Fang, Y., Liu, D., Chen, Q., & Ren, X. (2026). Pharmacokinetics, Bioequivalence, and Safety Evaluation of Two Voriconazole Tablets in Healthy Chinese Volunteers. Clinical Pharmacology in Drug Development, 15(4). https://doi.org/10.1002/cpdd.70058
Vancouver
Luo P, Lei Y, Liu C, Du J, Deng X, Yu H, et al. Pharmacokinetics, Bioequivalence, and Safety Evaluation of Two Voriconazole Tablets in Healthy Chinese Volunteers. Clinical Pharmacology in Drug Development. 2026;15(4). doi:10.1002/cpdd.70058
BibTeX
@article{Luo2026,
author = {Luo, Pan and Lei, Yongfang and Liu, Chang and Du, Juan and Deng, Xiangxiao and Yu, Hengyi and Qi, Xingxing and He, Zheng and Zhang, Dongling and Zuo, Qin and Fang, Yinian and Liu, Dong and Chen, Qian and Ren, Xiuhua},
title = {Pharmacokinetics, Bioequivalence, and Safety Evaluation of Two Voriconazole Tablets in Healthy Chinese Volunteers},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
volume = {15},
number = {4},
doi = {10.1002/cpdd.70058}
}
EUVIMED